Navigation Links
Experimental agents may prevent radiation-induced leukemia
Date:4/19/2009

DENVER Treatment with biphosphonates could prevent radiation-induced leukemia, according to data presented at the American Association for Cancer Research 100th Annual Meeting 2009.

Alexandra Miller, Ph.D., a senior scientist at the Armed Forces Radiobiology Research Institute, said her research is designed to help military and space agency personnel, who are more likely to be exposed to risky levels of radiation than the general population. However, she said the research could have applications for civilian populations as well.

"It is possible, although not yet proven, that the compound we studied could have a general effect on leukemia associated with causes other than radiation, such as age, which is much more common," said Miller.

The compounds Miller studied are biphosphonates known to scientists as ethane-1-hydroxy-1, 1-biphosphonate (EHBP) and carballylic amido bis phosphonic acid (CAPBP). Biphosphonates have emerged as an attractive chemopreventive agent due to earlier research that suggests they prevent bone metastasis and because they have an ability to remove uranium from the body.

For the current study, Miller and her colleagues irradiated laboratory mice at 3.5 Gy; all of the mice who were not treated with either EHBP or CAPBP developed leukemia.

By contrast, if they were treated with six doses of EHBP only 75 percent of mice developed leukemia. Similarly, only 65 percent of mice treated with CAPBP developed leukemia.


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. Experimental insulin-like growth factor receptor inhibitor reduced pancreatic cancer growth
2. Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis
3. Experimental Drug May Dampen Severe Asthma
4. Experimental Drug May Prevent Plaque Buildup
5. Experimental Biology 2009 meets April 18-22
6. Experimental Weight-Loss Pill Passes Early Test
7. Experimental Drug Fights Bone Marrow Cancers
8. Experimental Vaginal Gel Doesnt Ward Off HIV
9. Experimental TB drug explodes bacteria from the inside out
10. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
11. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... M&S ... Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's ... standards and specifications such as ANSI, ISO and proven test methods used in ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research ... strategy, having the skills needed to execute that strategy, and the actual success ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the American Cancer ... stages, is more than 95%. Once the cancer spreads to other organs, bones, or ... find out how to avoid this latter group, tune in to Lifestyle Magazine ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... ... at the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate ... and will be an opportunity for area-residents to celebrate two great years while ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... TEL AVIV, Israel , March 27, 2017 ... focused on oncology and immunology, announced today that AGI-134, an ... recently announced acquisition of Agalimmune Ltd., will be featured at ... Meeting in Washington, DC to ... ...
Breaking Medicine Technology: